PubMed · 11249694
VP-14637 ViroPharma.
Abstract
VP-14637 is the lead compound in a series of low molecular weight viral replication inhibitors which are under preclinical investigation by ViroPharma for the potential treatment of RSV infection [322651]. Phase I trials designed to evaluate the safety and pharmacokinetic prpfile of VR-14637 in healthy human volunteers have begun [385870]. VP-14637 is most active against pneumoviruses and the available data suggest that it is an inhibitor of RSV viral fusion activity [363716], [361097].
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
J McKimm-Breschkin. 2000. VP-14637 ViroPharma.. https://pubmed.ncbi.nlm.nih.gov/11249694/
Cite the original work for its findings. Save a collection to share your selection of sources.